Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin

Maturitas

Volumn 55, Issue 2, 2006, Pages 103-115

  Anderson, Garnet L ^a   Chlebowski, Rowan T ^b   Rossouw, Jacques E ^c   Rodabough, Rebecca J ^a   McTiernan, Anne ^a   Margolis, Karen L ^d   Aggerwal, Anita ^e   David Curb, J ^f   Hendrix, Susan L ^g   Allan Hubbell, F ^h   Khandekar, Jamardan ⁱ   Lane, Dorothy S ^j   Lasser, Norman ^k   Lopez, Ana Maria ^l   Potter, JoNell ^m   Ritenbaugh, Cheryl ^l  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

^f UNIVERSITY OF HAWAII   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j STONY BROOK UNIVERSITY   (United States)

^k UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^l UNIVERSITY OF ARIZONA   (United States)

^m UNIVERSITY OF MIAMI   (United States)

more..

Author keywords

Breast neoplasms; Estrogen; Progestin; Randomized trials; Subgroup analyses

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; INCIDENCE; MENOPAUSAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK FACTOR; TREATMENT DURATION;

AGED; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; RISK FACTORS; WOMEN'S HEALTH;

EID: 33748119290     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.05.004     Document Type: Article

References (21)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. Chlebowski R.T., Hendrix S.L., Langer R.D., et al., Women's Health Initiative Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289 22 (2003) 3243-3253
3. Colditz G.A., Hankinson S.E., Hunter D.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332 24 (1995) 1589-1593
4. Li C.I., Malone K.E., Porter P.L., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 22 (2003) 3254-3263
5. Olsson H.L., Ingvar C., and Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97 6 (2003) 1387-1392
6. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
7. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92 (2000) 328-332
8. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., and Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 (2000) 785-791
9. FDA News Release. FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women Following Review of Women's Health Initiative Data. January 8, 2003. Available at http://www.fda.gov/cder/drug/infopage/estrogens_progestins. Last accessed on June 15, 2006.
10. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 1 (2004) 47-53
11. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19 (1998) 61-109
12. Anderson G.L., Manson J., Wallace R., et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 13 9S (2003) S5-S17
13. Hays J., Hunt J.R., Hubbel A., et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13 9S (2003) S18-S77
14. Curb D., McTiernan A., Heckbert S.R., et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 13 9S (2003) S122-S128
15. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (1989) 1879-1886
16. Guthrie J.R., Dennerstein L., Hopper J.L., and Burger H.G. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol 88 (1996) 437-442
17. Overlie I., Moen M.H., Holte A., and Finset A. Androgens and estrogen in relation to hot flashes during the menopausal transition. Maturitas 41 1 (2002) 69-77
18. Cauley J.A., Lucas F.L., Kuller L.H., Stone K., Browner W., and Cummings S.R. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 130 (1999) 270-277
19. Prasad R., Boland G.P., Cramer A., et al. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer 98 12 (2003) 2539-2546
20. Howell A., Dodwell D.J., Anderson H., and Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3 8 (1992) 587-588
21. Colditz G.A. Estrogen, estrogen plus progestin therapy and risk of breast cancer. Clin Cancer Res 11 (2005) 909s-917s